These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 33929089)

  • 21. The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.
    Shadick NA; Gerlanc NM; Frits ML; Stolshek BS; Brady BL; Iannaccone C; Collier D; Cui J; Mutebi A; Weinblatt ME
    Clin Rheumatol; 2019 Nov; 38(11):3081-3092. PubMed ID: 31353421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4).
    Tanaka Y; Takeuchi T; Kato D; Kaneko Y; Fukuda M; Izutsu H; Rokuda M; van der Heijde D
    Mod Rheumatol; 2023 Jan; 33(1):73-80. PubMed ID: 35267027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis.
    Genovese MC; Sanchez-Burson J; Oh M; Balazs E; Neal J; Everding A; Hala T; Wojciechowski R; Fanjiang G; Cohen S
    Arthritis Res Ther; 2020 Mar; 22(1):60. PubMed ID: 32216829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
    Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S
    Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of peficitinib in rheumatoid arthritis.
    Kaneko Y
    Mod Rheumatol; 2020 Sep; 30(5):773-778. PubMed ID: 32643492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
    Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.
    Burmester GR; McInnes IB; Kremer J; Miranda P; Korkosz M; Vencovsky J; Rubbert-Roth A; Mysler E; Sleeman MA; Godwood A; Sinibaldi D; Guo X; White WI; Wang B; Wu CY; Ryan PC; Close D; Weinblatt ME;
    Ann Rheum Dis; 2017 Jun; 76(6):1020-1030. PubMed ID: 28213566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exposure-Response Modeling and Power Analysis of Components of ACR Response Criteria in Rheumatoid Arthritis (Part 2: Continuous Model).
    Li L; Zhang Y; Ma L; Ji P; Yim S; Chowdhury BA; Doddapaneni S; Liu J; Wang Y; Sahajwalla C
    J Clin Pharmacol; 2017 Sep; 57(9):1107-1125. PubMed ID: 28817201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical endpoint sensitivity in rheumatoid arthritis: modeling and simulation.
    Ma L; Zhao L; Xu Y; Yim S; Doddapaneni S; Sahajwalla CG; Wang Y; Ji P
    J Pharmacokinet Pharmacodyn; 2014 Oct; 41(5):537-43. PubMed ID: 25283268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
    Taylor PC; Saurigny D; Vencovsky J; Takeuchi T; Nakamura T; Matsievskaia G; Hunt B; Wagner T; Souberbielle B;
    Arthritis Res Ther; 2019 Apr; 21(1):101. PubMed ID: 30999929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis.
    Fleischmann RM; Damjanov NS; Kivitz AJ; Legedza A; Hoock T; Kinnman N
    Arthritis Rheumatol; 2015 Feb; 67(2):334-43. PubMed ID: 25385260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE.
    Li ZG; Hu JK; Li XP; Yang Y; Li XF; Xu JH; Zhang X; Xu J; Bao CD; He DY; Li ZJ; Wang GC; Zuo XX; Liu Y; Xiao ZY; Chen JW; Xin XF; Li JY; Jiang LD; Liu MR; Ji F; Li CG
    Adv Ther; 2021 Jan; 38(1):772-781. PubMed ID: 33237533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.
    Genovese MC; Greenwald M; Cho CS; Berman A; Jin L; Cameron GS; Benichou O; Xie L; Braun D; Berclaz PY; Banerjee S
    Arthritis Rheumatol; 2014 Jul; 66(7):1693-704. PubMed ID: 24623718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Cohen S; Hurd E; Cush J; Schiff M; Weinblatt ME; Moreland LW; Kremer J; Bear MB; Rich WJ; McCabe D
    Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study.
    Stock T; Fleishaker D; Wang X; Mukherjee A; Mebus C
    Int J Rheum Dis; 2017 Aug; 20(8):960-970. PubMed ID: 28328159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ultrasound of metacarpophalangeal joints is a sensitive and reliable endpoint for drug therapies in rheumatoid arthritis: results of a randomized, two-center placebo-controlled study.
    Seymour MW; Kelly S; Beals CR; Malice MP; Bolognese JA; Dardzinski BJ; Cheng AS; Cummings CE; Smugar SS; McClinton C; Fox A; Dooley WM; Pitzalis C; Taylor PC
    Arthritis Res Ther; 2012 Sep; 14(5):R198. PubMed ID: 22972032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
    Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings.
    Genovese MC; Yang F; Østergaard M; Kinnman N
    Ann Rheum Dis; 2016 Nov; 75(11):1979-1983. PubMed ID: 27084959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peroxisome proliferator-activated receptor γ agonist effect on rheumatoid arthritis: a randomized controlled trial.
    Ormseth MJ; Oeser AM; Cunningham A; Bian A; Shintani A; Solus J; Tanner S; Stein CM
    Arthritis Res Ther; 2013; 15(5):R110. PubMed ID: 24020899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exposure-Response Modeling Analyses for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin 6, in Patients With Moderately to Severely Active Rheumatoid Arthritis.
    Xu Y; Hu C; Zhuang Y; Hsu B; Xu Z; Sharma A; Zhou H
    J Clin Pharmacol; 2018 Nov; 58(11):1501-1515. PubMed ID: 29901815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.